Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Healthcare diagnostics momentum backed by Q2 record revenue of $622.7M, adjusted EBITDA of $99.7M, ARR up to $105.5M from $53.5M YoY, raised 2026 Imaging Center guidance, reaffirmed Digital Health guidance, and multiple FDA 510(k) clearances.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Profitability Rebound ⢠Rising Debt ⢠Strong Cash Flow RDNT's improving profitability and strong cash flow are offset by rising leverage, weak interest coverage, and demanding valuation, warranting caution.
Price Behavior
Key Price Behavior Insights: ⢠Recent rebound ⢠Neutral momentum ⢠Breakout trigger Support Level: $73.70â$74.30; major support $70.90â$71.00 Resistance Level: $75.50â$76.00; key resistance $76.80â$77.30 RDNT is stabilizing after last month's weakness, with a breakout above $76.80â$77.30 bullish and a drop below $73.70 risking a retest of $71.00.
Sentiment & News
Key News Insights: ⢠Institutional Accumulation ⢠Conference Presence ⢠Patient Outreach RadNet's news flow highlights institutional buying, investor visibility, and healthcare outreach, supporting market attention ahead of upcoming presentations.
AI Summary
RDNT warrants a hold/watch stance: accelerating imaging volumes and DeepHealth ARR could justify a platform re-rating only if they translate into sustained Digital Health profitability, stronger EPS/free-cash-flow conversion, and improved interest coverage; otherwise, its leveraged balance sheet and ~25x EV/EBITDA valuation leave meaningful downside.
Description
RadNet, Inc. operates a network of outpatient diagnostic imaging centers across multiple U.S. states, providing services such as MRI, CT, PET, mammography and other multimodality imaging procedures. The company also supplies imaging IT systems, including picture archiving and communication solutions, and has developed software tools to support radiologist interpretation in areas including mammography, lung and prostate cancer. Founded in 1981 and headquartered in Los Angeles, RadNet owned and managed 347 centers as of December 31, 2021.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 10 | Aug 17 | RDNT | RadNet, Inc. | Healthcare diagnostics momentum backed by Q2 record revenue of $622.7M, adjusted EBITDA of $99.7M, ARR up to $105.5M from $53.5M YoY, raised 2026 Imaging Center guidance, reaffirmed Digital Health guidance, and multiple FDA 510(k) clearances. | Closed | -1.8% |
| Sep 8 | Sep 15 | RDNT | RadNet, Inc. | RadNet shows strong Q2 operational momentum with record revenue and EBITDA growth, raised full-year guidance, expanding reimbursement streams, and technical momentum with a ~36% surge over 21 trading days; near-term price upside possible above resistance at ~$73, despite high leverage and valuation risks. | Closed | +4.2% |